InnoCare Pharma (9969) Q3 2025 earnings summary

Executive summary

• Total revenue for the first three quarters of 2025 reached RMB1.12 billion, up 59.85% year-over-year, driven by strong core product performance and licensing deals, including Prolium Bioscience Inc.

• Orelabrutinib sales hit RMB1.01 billion, up 45.77% year-over-year, supported by new indications and inclusion in clinical guidelines.

• Net loss narrowed significantly to RMB72 million, a 74.78% reduction year-over-year, reflecting improved cost efficiency and revenue growth.

• Gross profit margin improved to 88.8%, a 2.8 percentage point increase from the prior year.

• Cash position remained robust at RMB7.8 billion as of September 30, 2025, supporting ongoing R&D and globalization.

Financial highlights

• Operating revenue for Q3 2025 was RMB383.9 million, up 38.09% year-over-year.

• Drug sales contributed RMB1.024 billion, up 47.4% year-over-year.

• R&D expenses increased 9.9% year-over-year to RMB676 million, reflecting strategic investment in clinical trials and technology platforms.

• Net cash flows from operating activities improved to -RMB84.3 million from -RMB333.1 million year-over-year.

• Basic and diluted EPS for the nine-month period were both -0.04 RMB.

Outlook and guidance

• Full-year 2025 revenue expected to exceed RMB2.0 billion, representing over 100% year-over-year growth.

• Breakeven for the full year 2025 is anticipated, with sustainable profitability targeted two years ahead of schedule.

• Management plans to accelerate pipeline development and expand treatment options, leveraging strong cash reserves.